{"denoms":[{"counts":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"40"},{"groupId":"BG003","value":"50"}],"units":"Participants"}],"groups":[{"description":"Romidepsin 9mg/m\\^2 by intravenous (IV) infusion on Days 1, 8, 15 of each 28-day cycle","id":"BG000","title":"Phase 1: Romidepsin 9mg/m^2"},{"description":"Romidepsin 14mg/m\\^2 by intravenous (IV) infusion on Days 1, 8, 15 of each 28-day cycle.","id":"BG001","title":"Phase 1: Romidepsin 14mg/m^2"},{"description":"Romidepsin 14mg/m\\^2 by intravenous (IV) infusion on Days 1, 8, 15 of each 28-day cycle.","id":"BG002","title":"Phase 2: Romidepsin 14mg/m^2"},{"description":"Total of all reporting groups","id":"BG003","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.54","value":"59.0"},{"groupId":"BG001","spread":"4.20","value":"73.6"},{"groupId":"BG002","spread":"8.43","value":"68.5"},{"groupId":"BG003","spread":"8.47","value":"68.7"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"12"},{"groupId":"BG003","value":"14"}]}],"title":"<65 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"28"},{"groupId":"BG003","value":"36"}]}],"title":"≥65 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"17"},{"groupId":"BG003","value":"21"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"23"},{"groupId":"BG003","value":"29"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"40"},{"groupId":"BG003","value":"48"}]}],"title":"PTCL"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}]}],"title":"CTCL"}],"description":"PTCL is included in a heterogenous group of rare diseases resulting from clonal proliferation of mature thymic lymphocytes. These T-cell tumors account for about 10% to 15% of all lymphoid tumors. CTCL is a non-Hodgkin's lymphoma of helper T-cells that usually presents in the skin. It is classified mainly into mycosis fungoides and Sézary syndrome, and the stage is classified by the Tumor Node Metastasis Blood (TNMB) classification.","paramType":"NUMBER","title":"Disease Type by Investigator","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"22"},{"groupId":"BG003","value":"26"}]}],"title":"0 = (Fully Active)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"17"}]}],"title":"1 = (Restrictive but ambulatory)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"7"}]}],"title":"2 = (Ambulatory but unable to work)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}],"title":"3 = (Limited self care)"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]}],"title":"4 = (Completely Disabled)"}],"description":"Eastern Cooperative Oncology Group (ECOG) performance status is used by doctors and researchers to assess how a participant's disease is progressing, assess how the disease affects the daily living activities of the participant and determine appropriate treatment and prognosis. 0 = Fully Active (Most Favorable Activity); 1 = Restricted activity but ambulatory; 2 = Ambulatory but unable to carry out work activities; 3 = Limited Self-Care; 4 = Completely Disabled, No self-care (Least Favorable Activity)","paramType":"NUMBER","title":"Eastern Cooperative Oncology Group (ECOG)","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"0.1114","value":"1.640"},{"groupId":"BG001","spread":"0.2034","value":"1.563"},{"groupId":"BG002","spread":"0.1768","value":"1.554"},{"groupId":"BG003","spread":"0.1757","value":"1.561"}]}]}],"description":"BSA is the total surface area of the body and was used to calculate the dosage for romidepsin.","dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Body Surface Area (BSA)","unitOfMeasure":"m2"}],"populationDescription":"Intent to Treat (ITT) includes all participants who received at least one dose of romidepsin."}